Peter Bernhardt

Dr. Peter Bernhardt is the Head of CMC (Chemistry, Manufacturing, and Controls) at ModeX, overseeing process development, analytical and formulation development, manufacturing, and quality control. 

With extensive CMC leadership experience at Greenlight Bio, Magenta, BMS, Celgene, Momenta, and Shire, Dr. Bernhardt has a proven track record of advancing biologic candidates from preclinical research through commercialization. His expertise spans a wide range of modalities, including monoclonal antibodies, Fc fusion proteins, antibody-drug conjugates, enzymes, ferritin nanoparticles, and nucleotide delivery platforms. 

Dr. Bernhardt holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology (MIT) and an MSc in Biotechnology from Royal Institute of Technology (KTH) in Stockholm, Sweden. He conducted postdoctoral research as a NIH NRSA Postdoctoral Fellow at the University of California, San Diego.